German Reyes-Botero1, Caroline Dehais, Ahmed Idbaih, Nadine Martin-Duverneuil, Marion Lahutte, Catherine Carpentier, Eric Letouzé, Olivier Chinot, Hugues Loiseau, Jerome Honnorat, Carole Ramirez, Elisabeth Moyal, Dominique Figarella-Branger, François Ducray. 1. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France (G.R.B., C.D., A.I.); Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière, Paris, France (A.I., C.C.); AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neuro-radiologie, Paris, France (N.M.-D.); Service de Santé des Armées, Hôpital d'Instruction des Armées, Paris, France (M.L.); Programme Carte d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France (E.L.); AP-HM, Hôpital de la Timone, Service de Neuro-Oncologie, Marseille , France (O.C.); CHU Bordeaux, Hôpital Pellegrin, Service de Neurochirurgie, Bordeaux, France (H.L.); Hospices Civils de Lyon, Hôpital Pierre Wertheimer, Service de Neuro-Oncologie, Bron, France (J.H., F.D.); INSERM U1028, CNRS UMR5292, Bron, France (J.H., F.D.); CHU Lille, Hôpital Roger Salengro, Clinique de Neurochirurgie, Lille, France (C.R.); Institut Claudius Regaud, Département de Radiothérapie, Toulouse, France (E.M.); AP-HM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France (D.F.-B.); Université de la Méditerranée, Aix-Marseille, Faculté de Médecine La Timone, Marseille, France (D.F.B.).
Abstract
BACKGROUND: The aim of this study was to correlate MRI features and molecular characteristics in anaplastic oligodendrogliomas (AOs). METHODS: The MRI characteristics of 50 AO patients enrolled in the French national network for high-grade oligodendroglial tumors were analyzed. The genomic profiles and IDH mutational statuses were assessed using high-resolution single-nucleotide polymorphism arrays and direct sequencing, respectively. The gene expression profiles of 25 1p/19q-codeleted AOs were studied on Affymetrix expression arrays. RESULTS: Most of the cases were frontal lobe contrast-enhanced tumors (52%), but the radiological presentations of these cases were heterogeneous, ranging from low-grade glioma-like aspects (26%) to glioblastoma-like aspects (22%). The 1p/19q codeletion (n = 39) was associated with locations in the frontal lobe (P = .001), with heterogeneous intratumoral signal intensities (P = .003) and with no or nonmeasurable contrast enhancements (P = .01). The IDH wild-type AOs (n = 7) more frequently displayed ringlike contrast enhancements (P = .03) and were more frequently located outside of the frontal lobe (P = .01). However, no specific imaging pattern could be identified for the 1p/19q-codeleted AO or the IDH-mutated AO. Within the 1p/19q-codeleted AO, the contrast enhancement was associated with larger tumor volumes (P = .001), chromosome 9p loss and CDKN2A loss (P = .006), genomic instability (P = .03), and angiogenesis-related gene expression (P < .001), particularly for vascular endothelial growth factor A and angiopoietin 2. CONCLUSION: In AOs, the 1p/19q codeletion and the IDH mutation are associated with preferential (but not with specific) imaging characteristics. Within 1p/19q-codeleted AO, imaging heterogeneity is related to additional molecular alterations, especially chromosome 9p loss, which is associated with contrast enhancement and larger tumor volume.
BACKGROUND: The aim of this study was to correlate MRI features and molecular characteristics in anaplastic oligodendrogliomas (AOs). METHODS: The MRI characteristics of 50 AO patients enrolled in the French national network for high-grade oligodendroglial tumors were analyzed. The genomic profiles and IDH mutational statuses were assessed using high-resolution single-nucleotide polymorphism arrays and direct sequencing, respectively. The gene expression profiles of 25 1p/19q-codeleted AOs were studied on Affymetrix expression arrays. RESULTS: Most of the cases were frontal lobe contrast-enhanced tumors (52%), but the radiological presentations of these cases were heterogeneous, ranging from low-grade glioma-like aspects (26%) to glioblastoma-like aspects (22%). The 1p/19q codeletion (n = 39) was associated with locations in the frontal lobe (P = .001), with heterogeneous intratumoral signal intensities (P = .003) and with no or nonmeasurable contrast enhancements (P = .01). The IDH wild-type AOs (n = 7) more frequently displayed ringlike contrast enhancements (P = .03) and were more frequently located outside of the frontal lobe (P = .01). However, no specific imaging pattern could be identified for the 1p/19q-codeleted AO or the IDH-mutated AO. Within the 1p/19q-codeleted AO, the contrast enhancement was associated with larger tumor volumes (P = .001), chromosome 9p loss and CDKN2A loss (P = .006), genomic instability (P = .03), and angiogenesis-related gene expression (P < .001), particularly for vascular endothelial growth factor A and angiopoietin 2. CONCLUSION: In AOs, the 1p/19q codeletion and the IDH mutation are associated with preferential (but not with specific) imaging characteristics. Within 1p/19q-codeleted AO, imaging heterogeneity is related to additional molecular alterations, especially chromosome 9p loss, which is associated with contrast enhancement and larger tumor volume.
Entities:
Keywords:
1p19q co-deletion; IDH mutation; SNP array; anaplastic oligodendroglioma; magnetic resonance imaging
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Andrew C Newman; Wayne Chou; Katrina M Welch-Reardon; Ashley H Fong; Stephanie A Popson; Duc Thien Phan; Daniel R Sandoval; Dananh P Nguyen; Paul D Gershon; Christopher C W Hughes Journal: Arterioscler Thromb Vasc Biol Date: 2013-01-03 Impact factor: 8.311
Authors: Michael D Jenkinson; Trevor S Smith; Andrew R Brodbelt; Kathy A Joyce; Peter C Warnke; Carol Walker Journal: J Magn Reson Imaging Date: 2007-12 Impact factor: 4.813
Authors: Serena Marchiò; Johanna Lahdenranta; Reinier O Schlingemann; Donatella Valdembri; Pieter Wesseling; Marco A Arap; Amin Hajitou; Michael G Ozawa; Martin Trepel; Ricardo J Giordano; David M Nanus; Henri B P M Dijkman; Egbert Oosterwijk; Richard L Sidman; Max D Cooper; Federico Bussolino; Renata Pasqualini; Wadih Arap Journal: Cancer Cell Date: 2004-02 Impact factor: 31.743
Authors: M Labussière; A Idbaih; X-W Wang; Y Marie; B Boisselier; C Falet; S Paris; J Laffaire; C Carpentier; E Crinière; F Ducray; S El Hallani; K Mokhtari; K Hoang-Xuan; J-Y Delattre; M Sanson Journal: Neurology Date: 2010-04-28 Impact factor: 11.800
Authors: Shanshan Jiang; Tianyu Zou; Charles G Eberhart; Maria A V Villalobos; Hye-Young Heo; Yi Zhang; Yu Wang; Xianlong Wang; Hao Yu; Yongxing Du; Peter C M van Zijl; Zhibo Wen; Jinyuan Zhou Journal: Magn Reson Med Date: 2017-07-16 Impact factor: 4.668
Authors: David W Nauen; Andrew Guajardo; Lisa Haley; Kerry Powell; Peter C Burger; Christopher D Gocke Journal: Converg Sci Phys Oncol Date: 2015-06-16
Authors: Rachel L Delfanti; David E Piccioni; Jason Handwerker; Naeim Bahrami; AnithaPriya Krishnan; Roshan Karunamuni; Jona A Hattangadi-Gluth; Tyler M Seibert; Ashwin Srikant; Karra A Jones; Vivian S Snyder; Anders M Dale; Nathan S White; Carrie R McDonald; Nikdokht Farid Journal: J Neurooncol Date: 2017-09-04 Impact factor: 4.130